On October 9, CRISPR Therapeutics AG rose 5.31% in regular trading, trading at $53.05/share, with Turnover of $28.91 million.

The move came as Bank of America slightly lowered its price target on the stock to $81 from $82 while maintaining a Buy rating. FactSet data shows the analyst consensus rating remains overweight with an average price target of $84.67, significantly above current levels.

On the fundamentals front, the company has recently released multiple clinical updates, including positive Phase 1b data for CTX310 at the AHA Scientific Sessions and ESC Congress, as well as Phase 1 clinical data for Zugo-cel in autoimmune disease, suggesting several late-stage catalysts may be approaching.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)